encorafenib

{
  "id": "MLC-T-ONC-002792",
  "term": "encorafenib",
  "field": "Oncology and biomedicine",
  "definitions": [
    "A drug used with cetuximab to treat certain types of colorectal cancer and with binimetinib to treat certain types of melanoma and non-small cell lung cancer. It is used in patients whose cancer has a certain mutation (change) in the BRAF gene. It is also being studied in the treatment of other types of cancer. Encorafenib blocks certain proteins made by the mutated BRAF gene, which may help keep cancer cells from growing. It is a type of kinase inhibitor. Also called Braftovi.",
    "An orally available Raf kinase inhibitor with potential antineoplastic activity. Encorafenib specifically inhibits Raf kinase, a serine/threonine enzyme in the RAF/mitogen-activated protein kinase kinase (MEK)/extracellular signal-related kinase (ERK) signaling pathway. By inhibiting the activation of the RAF/MEK/ERK signaling pathway, the administration of encorafenib may result in a decrease in proliferation of tumor cells. The Raf mutation BRAF V600E is frequently upregulated in a variety of human tumors and results in the constitutive activation of the RAF/MEK/ERK signaling pathway that regulates cellular proliferation and survival."
  ],
  "synonyms": [
    "Braftovi"
  ],
  "references": [
    "NCI Dictionary of Cancer Terms",
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/encorafenib/"
}